• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Episode 77: The Effects of AI on IP

Podcast

Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent with the firm, discuss IP strategy as it relates to pharma and artificial intelligence.

Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent at the firm, talk about the increasing use of artificial intelligence in pharma and how that is affecting the realm of intellectual property.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Related Videos
Related Content
Our Top 5 Podcast Episodes of 2023

Our Top 5 Podcast Episodes of 2023

December 27th 2023
Article

Our top five episodes of the year.

Fierce Females in the Life Science Space

Fierce Females in the Life Science Space

March 29th 2024
Podcast

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

Site Logo

Episode 67: Succeeding Through Adversity

October 15th 2020
Article

Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.

Gen-Z Influence on Pharma M&A

Gen-Z Influence on Pharma M&A

March 14th 2024
Podcast

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Site Logo

Episode 60: Leading With Compassion

July 9th 2020
Article

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing a company through COVID-19, in light of the fact that he himself is immunocompromised.

Site Logo

Episode 59: Using Tau to Target Alzheimer’s

June 25th 2020
Article

Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.